ASP Isotopes (ASPI) Projected to Release Quarterly Earnings on Thursday

Key Points

• ASP Isotopes is expected to report Q3 2026 results on November 12, with analysts forecasting a loss of $0.15 per share and revenue of $5.68 million. The earnings call is scheduled for November 20.
• In its prior quarter, the company posted an EPS loss of $0.28, missing estimates of a $0.17 loss, while revenue of $5.12 million exceeded the $4.47 million consensus.
• Analysts have a consensus Hold rating and a $12 average price target; the stock recently opened at $1.91, near its 52-week low of $1.78.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) is expected to announce its Q3 2026 resultson Thursday, November 12th. Analysts expect ASP Isotopes to announce earnings of ($0.15) per share and revenue of $5.68 million for the quarter. Individuals can check the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 20, 2026 at 8:30 AM ET.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.11). ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%. The company had revenue of $5.12 million for the quarter, compared to the consensus estimate of $4.47 million.

ASP Isotopes Trading Up 5.5%

Shares of ASP Isotopes stock opened at $1.91 on Thursday. ASP Isotopes has a 52 week low of $1.78 and a 52 week high of $9.38. The stock has a 50 day moving average price of $2.85 and a two-hundred day moving average price of $4.79. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.87 and a quick ratio of 3.85.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ASPI shares. Weiss Ratings restated a "sell (d-)" rating on shares of ASP Isotopes in a report on Monday, September 21st. Wall Street Zen upgraded ASP Isotopes from a "strong sell" rating to a "sell" rating in a report on Saturday, August 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $12.00.

Insider Activity

In other news, CFO Heather Kiessling sold 21,830 shares of the company's stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $2.19, for a total value of $47,807.70. Following the completion of the transaction, the chief financial officer directly owned 1,504,422 shares of the company's stock, valued at $3,294,684.18. This represents a 1.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Paul Mann sold 83,759 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $4.10, for a total value of $343,411.90. Following the sale, the chief executive officer directly owned 9,328,570 shares of the company's stock, valued at $38,247,137. The trade was a 0.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 245,285 shares of company stock worth $899,887 in the last quarter. 14.40% of the stock is owned by corporate insiders.

About ASP Isotopes

ASP Isotopes Inc is a materials and technology company developing isotope-enrichment processes for use in the medical, semiconductor and nuclear-energy industries. Its primary technology is the Aerodynamic Separation Process, a proprietary method designed to separate isotopes based on differences in molecular mass and aerodynamic behavior.

The company is pursuing the production of enriched isotopes, including materials intended for applications such as semiconductor manufacturing, medical diagnostics and treatment, advanced nuclear fuels, and other industrial and scientific uses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.